 |
|
|
| |
Safety, Efficacy, and Clinical Outcomes in
Hepatitis C Virus Genotype 1-Infected Patients
Receiving Ombitasvir/Paritaprevir/Ritonavir +
Dasabuvir ± Ribavirin in the TOPAZ-I and TOPAZ-II Trials
|
| |
| |
Reported by Jules Levin
26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), 15-19 February 2017, Shanghai, China
J George1, D Dieterich2, M Weltman3, R Skoien4, P Desmond5, J Sasadeusz6, KA Stuart7, P Dorr8, E Dumas8, M Charafeddine8, L Liu8, D Cohen8, P Martin9, HS Te10, M Sulkowski 11, D Shaw12, F Poordad13
1Westmead Hospital, Westmead, New South Wales, Australia; 2Icahn School of Medicine at Mount Sinai, New York, New York, United States; 3Nepean Hospital, Kingswood, New South Wales, Australia; 4Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia; 5St. Vincents Hospital Melbourne, Fitzroy, Victoria, Australia; 6Royal Melbourne Hospital, Parkville, Victoria, Australia; 7Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia; 8AbbVie Inc., North Chicago, Illinois, United States; 9University of Miami,
Miami, Florida, United States; 10University of Chicago, Chicago, Illinois, United States; 11Johns Hopkins University, Lutheville, Maryland, United States; 12Royal Adelaide Hospital, Adelaide, South Australia, Australia; 13Texas Liver Institute, San Antonio, Texas, United States
|
| |
|
|
|
|
|
